Group A Streptococcus for injection

Experiments have shown that group A streptococci have the function of directly killing tumor cells, activating host cell immunity, and increasing the activity of T cells and NK cells; combined with chemotherapy, it can improve the efficacy and may reduce the effect of chemotherapy drugs on the bone marrow, and can regulate T cell subpopulations to increase the overall ratio of T3, T4, and T4/T8.

Main components: Group A hemolytic Streptococcus treated with penicillin.

This product is white powder with a slight odor. It becomes a white turbid liquid after being dissolved in physiological sodium chloride solution.

Clinical trials have shown that intracavitary treatment is effective in treating malignant pleural effusions, and intratumoral and systemic medications have certain effects on solid tumors. They can be used in conjunction with surgery, radiotherapy or chemotherapy for the adjuvant treatment of malignant tumors.

1 Intradermal or subcutaneous injection: The starting dose is 0.1 mg, which increases by 0.1 mg daily. On the 5th day, it increases to 0.5 mg. From the 6th day onwards, 0.5 mg is used daily. Depending on the tolerance, the dose can be increased to 1.0 mg per day (generally, the subcutaneous injection volume should not exceed 0.5 ml, and it should be fully shaken before injection). A full course of treatment is 30 days of administration. Depending on the patient's condition, a second course of treatment can be considered, 2 to 3 times a week, 0.5 mg to 1.0 mg each time, for 4 consecutive weeks. 2 Intratumor or tumor edge injection: Subcutaneous injection once a day, the starting dose is 0.1 mg, which increases by 0.1 mg daily, and increases to 0.5 mg on the 5th day. For surface tumor lesions, depending on the size of the tumor and the patient's condition, multiple injections are given into the tumor or at the edge of the tumor, 1.0 to 2.0 mg at a time, once a week. The dose can be appropriately increased depending on the patient's tolerance. A course of treatment is 4 weeks. During the interval between two intratumor injections, intradermal and subcutaneous injections should continue once a day at 0.5 to 1.0 mg. For intracavitary tumor lesions, intratumoral injection can be carefully performed by experienced specialists with the help of organoscopes. The amount of diluent can be controlled by the doctor according to the patient's condition. 3 Intracavitary injection: 3.1 Intrathoracic injection: First, inject 0.1 mg intradermally or subcutaneously daily, and then gradually increase to 0.5 mg daily. Then start intracavitary injection at the same time, 0.5-1.0 mg each time, dissolved with 10-20 ml of physiological sodium chloride solution, 1-2 times a week, 4 for a course of treatment. After intracavitary injection, the patient should change his position to increase the contact area between the drug solution and the lesion. 3.2 Intraserous cavity injection: 0.1 mg for the first time, 0.2 mg for the second time, 0.5 mg for the third time, and the maintenance dose is 0.5-1.0 mg each time, dissolved with 10-20 ml of physiological sodium chloride solution, and injected after suspension, 2-3 times a week, 2 weeks for a course of treatment, or follow the doctor's advice.

1. Subcutaneous injection sites may experience different degrees of pain, redness, swelling, nodules, blisters and other side effects. When repeated injections are performed, care should be taken to avoid the same site. When the pain is severe, this product can be diluted with 0.2% lidocaine. 2. Fever and allergic reactions may occur. Symptomatic treatment should be given when necessary, and the drug should be discontinued in time when an allergic reaction occurs. 3. There may be a mild, temporary decrease in hemoglobin or red blood cells, and there may also be a mild, temporary increase in leukocytosis. 4. Rarely, blood alkaline phosphatase, GOT, and GPT increase. If such reactions occur, appropriate measures such as discontinuation of the drug should be taken. 5. Symptoms include loss of appetite, nausea, vomiting, diarrhea, etc.

1. Those with a history of penicillin allergy are prohibited from using this product. 2. Those with heart disease, kidney disease, especially those with rheumatic heart disease are prohibited from using this product. 3. Those who are prone to asthma, rash, urticaria, etc., or their immediate family members are prohibited from using this product.

Not yet clear.

Store at 2~8℃.

1KE

Sinopharm Group Luya(Shandong)Pharmaceutical Co., Ltd.

• Founded in:

  2000-11-06

• Address:

  No. 3, Hongxing West Road, Rencheng District, Jining City, Shandong Province

• Tax NO.:

  91370800706117112C

• Registered Funds:

  24.5293 million yuan

• Website:

  Log in to view

• Email:

  Log in to view